EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study

Junfen Fu, Xinran Cheng, Michael Højby, Chunxiu Gong, Tina Lund Leunbach, Yanhong Li, Haiyan Wei, Yu Zhu, Yining Zhang, Yan Zhong

Hormone Research in Paediatrics · 2025

DOI: 10.1159/000545786 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Hormone Research in Paediatrics, 2025. Verfasst von Junfen Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou…. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

REAL6 is a randomized, multi-centre, open-labelled, active-controlled parallel group phase 3 trial (NCT04970654) investigating once-weekly somapacitan, a reversible albumin-binding growth hormone (GH) derivative, in Chinese children with GH deficiency (GHD).

Methods

110 treatment-naïve patients were randomized 2:1 to somapacitan (0.16 mg/kg/week) or daily GH (Norditropin®; 0.034 mg/kg/day) for 52 weeks. Annualized height velocity (HV; cm/year) at week 52 was the primary measurement. Additional assessments included HV standard deviation score (SDS), height SDS, bone age, insulin-like growth factor-I (IGF¬ I) SDS, and observer-reported outcomes.

Results

Estimated mean HV at week 52 was 11.0 and 10.4 cm/year for somapacitan and daily GH, respectively. Non-inferiority of somapacitan compared to daily GH was confirmed. Changes in HVSDS, height SDS, bone age, and IGF-I SDS from baseline to week 52 were similar between groups. At week 52, mean (SD) IGF-I SDS was within intended reference range (-2.0 to +2.0) and comparable between groups: +0.5 (1.4) for somapacitan versus +0.1 (1.2) for daily GH. Somapacitan was well-tolerated with a safety profile consistent with the well-known safety profile of daily GH. A low proportion of injection-site reactions were reported for somapacitan (2.7%), with no reports of injection-site pain during the 52-week treatment period. Disease burden was reduced from baseline to week 52 for both treatments. Somapacitan reduced treatment burden compared to daily GH.

Conclusions

Efficacy and safety profiles were comparable for Chinese children with GHD treated with somapacitan or daily GH. Both treatments similarly reduced disease burden, while treatment burden was reduced with somapacitan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneDwarfism, PituitaryHumansFemaleMaleChildChild, PreschoolInsulin-Like Growth Factor IBody HeightAdolescentChinaEast Asian People

Stichwörter der Autor:innen

Growth hormone deficiencyGrowth hormone replacement therapyHeightLong-acting growth hormoneSomapacitan

Substanzen

Human Growth HormoneInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Endocrinology Department, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, fjf68@zju.edu.cn.
  • Department of Pediatric Genetics, Endocrinology and Metabolism, Chengdu Women and Children's Center Hospital, Chengdu, China.
  • Clinical Development, Novo Nordisk A/S, Søborg, Denmark.
  • Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children Health, Beijing, China.
  • Department of PediatrIcs, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou, China.

Zitieren

APA

Fu, J., Cheng, X., Højby, M., Gong, C., Leunbach, T. L., Li, Y., Wei, H., Zhu, Y., Zhang, Y., & Zhong, Y. (2025). Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study. Hormone Research in Paediatrics. https://doi.org/10.1159/000545786

Vancouver

Fu J, Cheng X, Højby M, Gong C, Leunbach TL, Li Y, et al. Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study. Hormone Research in Paediatrics. 2025. doi:10.1159/000545786

BibTeX
@article{Fu2025,
  author = {Fu, Junfen and Cheng, Xinran and Højby, Michael and Gong, Chunxiu and Leunbach, Tina Lund and Li, Yanhong and Wei, Haiyan and Zhu, Yu and Zhang, Yining and Zhong, Yan},
  title = {Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study},
  journal = {Hormone Research in Paediatrics},
  year = {2025},
  doi = {10.1159/000545786}
}
Kostenlos starten →